This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Preoperative Hepatic Arterial Infusion Chemotherapy

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2007 by IRCCS San Raffaele.
Recruitment status was:  Active, not recruiting
Information provided by:
IRCCS San Raffaele Identifier:
First received: August 28, 2007
Last updated: NA
Last verified: May 2007
History: No changes posted
To assess the feasibility and results of liver resection after preoperative hepatic artery infusion (HAI) chemotherapy with FUDR.

Condition Intervention
Colorectal Liver Metastases Drug: Floxuridine FUDR

Study Type: Observational
Study Design: Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Retrospective
Official Title: Preoperative Hepatic Arterial Infusion Chemotherapy in Patients Undergoing Liver Resection for Colorectal Liver Metastases

Resource links provided by NLM:

Further study details as provided by IRCCS San Raffaele:

Study Start Date: December 1995
Detailed Description:

Between 1995 and 2004, 239 patients with isolated colorectal liver metastases received HAI chemotherapy with neoadjuvant intent. Fifty of these patients underwent subsequent curative liver resection (HAI group).

Postoperative morbidity, liver function tests, and long term outcomes were evaluated. Adverse events related to HAI chemotherapy were also evaluated.


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Unresectable liver metastases
  • Potentially resectable liver metastases

Exclusion Criteria:

  • Extrahepatic disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00522509

Department of Surgery - Liver Unit, Scientific Institute San Raffaele,
Milan, Italy, 20132
Sponsors and Collaborators
IRCCS San Raffaele
Principal Investigator: Luca Aldrighetti, M.D, PhD Department of Surgery - Liver Unit, Scientific Institute San Raffaele,
  More Information Identifier: NCT00522509     History of Changes
Other Study ID Numbers: Neoadjuvant HAIC
Study First Received: August 28, 2007
Last Updated: August 28, 2007

Additional relevant MeSH terms:
Neoplasm Metastasis
Liver Neoplasms
Neoplastic Processes
Pathologic Processes
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents processed this record on August 22, 2017